Differential Diagnosis

The FDA has granted accelerated approval to pirtobrutinib for the treatment of patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

The FDA breakthrough drug designation for epcoritamab in follicular lymphoma was supported by findings from the phase 1/2 EPCORE NHL-1 study.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

SIRPant-M has been granted orphan drug designation by the FDA for patients with T-cell lymphoma.

In an interview, Mwanasha Merrill discussed the implication of findings from a phase 2 trial of pembrolizumab after autologous stem cell transplantation for the treatment of patients with peripheral T-cell lymphoma.